Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Alliancebernstein L.P.

Alliancebernstein L.P. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,630 shares of the company’s stock after acquiring an additional 889 shares during the period. Alliancebernstein L.P. owned about 0.11% of Amphastar Pharmaceuticals worth $1,880,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in Amphastar Pharmaceuticals by 222.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock valued at $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust grew its position in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after buying an additional 871 shares during the last quarter. TD Private Client Wealth LLC grew its position in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares during the last quarter. KBC Group NV raised its stake in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after acquiring an additional 650 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Amphastar Pharmaceuticals by 90.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock worth $156,000 after acquiring an additional 1,992 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AMPH has been the subject of several recent research reports. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $23.35 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The stock has a market cap of $1.11 billion, a PE ratio of 7.78, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The business’s 50 day moving average is $27.96 and its 200-day moving average is $37.53. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.